Abstracts tagged "Mast cells"

Abstract Number: 1401 • 2017 ACR/ARHP Annual Meeting
Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Felice Rivellese, Frances Humby, Sara Pagani, Alessandra Nerviani and Costantino Pitzalis, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Mast cells (MCs) are immune cells infiltrating the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, but their strict contribution to disease…
Abstract Number: 3218 • 2016 ACR/ARHP Annual Meeting
Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby¹, Stephen Kelly¹, Amato de Paulis², Gianni Marone² and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
Background/Purpose: Mast cells (MCs) are immune cells present in the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, although their exact contribution…
Abstract Number: 934 • 2015 ACR/ARHP Annual Meeting
Platelet-Independent Role of Megakaryocytes in Antibody-Mediated Murine Arthritis
Pierre Cunin¹, Loka Penke², Jonathan Thon³, Paul A. Monach⁴, Tatiana Jones⁵, Mary Chen², Yoichiro Iwakura⁶, Jerry Ware⁷, Michael Gurish², Joseph Italiano³, Eric Boilard⁸ and Peter A. Nigrovic^2,9, ¹Rheumatology, Immunology and Allergy, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Department of Medicine, Hematology Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Department of Clinical Laboratory and Nutritional Science, University of Massachusetts Lowell, Lowel, MA, ⁶Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan, ⁷Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁸Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Faculté de Médecine de l’Université Laval, Quebec, QC, Canada, ⁹Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Mice bearing mutations affecting Kit (stem cell factor receptor) exhibit multiple hematologic phenotypes, including mast cell deficiency, and have been used to assess the…
Abstract Number: 850 • 2014 ACR/ARHP Annual Meeting
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Jacqueline E. Paramarta¹, Maureen C. Turina¹, Tanja F. Heijda², Iris C. Blijdorp³, Troy Noordenbos¹, Nataliya Yeremenko² and Dominique L. Baeten⁴, ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].